EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity

Raymond S Douglas iD, Steven Couch, Sara T Wester, Brian T Fowler, Catherine Y Liu, Prem S Subramanian, Rosa Tang, Quang T Nguyen, Robi N Maamari, Shoaib Ugradar, Kate Hsu, Michael Karon iD und 1 weitere

The Journal of Clinical Endocrinology & Metabolism · 21.12.2023 · 109 (1) · 25-35

DOI: 10.1210/clinem/dgad637 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 31.10.2023. Verfasst von Raymond S Douglas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA. Hauptthemen laut MEDLINE: Exophthalmos, Graves Ophthalmopathy. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Early inflammatory thyroid eye disease (TED) can lead to symptomatic chronic disease, including disabling proptosis. Teprotumumab, an insulin-like growth factor-1 receptor (IGF-1R) inhibitor, previously demonstrated efficacy in acute, high-inflammation TED trials.

Objective

We present data from the first placebo-controlled trial with teprotumumab in chronic/low disease activity TED.

Methods

This randomized double-masked, placebo-controlled trial, conducted at 11 US centers, enrolled adult participants with TED duration of 2 to 10 years, Clinical Activity Score (CAS) ≤ 1 or no additional inflammation or progression in proptosis/diplopia for ≥1 year, proptosis ≥3 mm from before TED and/or from normal, euthyroid/mildly hypo/hyperthyroid, no prior teprotumumab, and no steroids within 3 weeks of baseline. Patients received (2:1) intravenous teprotumumab or placebo once every 3 weeks (total 8 infusions). The primary endpoint was proptosis (mm) improvement at Week 24. Adverse events (AEs) were assessed.

Results

A total of 62 (42 teprotumumab and 20 placebo) patients were randomized. At Week 24, least squares mean (SE) proptosis improvement was greater with teprotumumab (−2.41 [0.228]) than with placebo (−0.92 [0.323]), difference −1.48 (95% CI −2.28, −0.69; P = .0004). Proportions of patients with AEs were similar between groups. Hyperglycemia was reported in 6 (15%) vs 2 (10%) and hearing impairment in 9 (22%) vs 2 (10%) with teprotumumab and placebo, respectively. AEs led to discontinuation in 1 teprotumumab (left ear conductive hearing loss with congenital anomaly) and 1 placebo patient (infusion-related). There were no deaths.

Conclusion

Teprotumumab significantly improved proptosis vs placebo in longstanding/low inflammation TED, demonstrating efficacy regardless of disease duration/activity. The safety profile was comparable to that previously reported.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExophthalmosGraves OphthalmopathyAdultHumansAntibodies, Monoclonal, HumanizedInflammationProtein Kinase InhibitorsDouble-Blind Method

Stichwörter der Autor:innen

Graves diseasechronicinactiveteprotumumabthyroid eye disease

Substanzen

Antibodies, Monoclonal, HumanizedProtein Kinase Inhibitorsteprotumumab

Autor:innen und Institutionen

  • Department of Ophthalmology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA.
  • John F. Hardesty MD Department of Ophthalmology and Visual Sciences, Washington University School of Medicine, St Louis, MO 63130, USA.
  • Bascom Palmer Eye Institute, University of Miami, Miami, FL 33136, USA.
  • Department of Ophthalmology, The University of Tennessee Health Science Center, Hamilton Eye Institute, Memphis, TN 38163, USA.
  • Department of Ophthalmology, Shiley Eye Institute, University of California San Diego, La Jolla, CA 92037, USA.
  • Departments of Ophthalmology, Neurology, and Neurosurgery, UC Health Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO 80045, USA.

ORCID-Profile: Raymond S Douglas, Michael Karon

Förderung

  • Horizon Therapeutics

Zitieren

APA

Douglas, R. S., Couch, S., Wester, S. T., Fowler, B. T., Liu, C. Y., Subramanian, P. S., Tang, R., Nguyen, Q. T., Maamari, R. N., Ugradar, S., Hsu, K., Karon, M., & Stan, M. N. (2023). Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. The Journal of Clinical Endocrinology & Metabolism, 109(1), 25-35. https://doi.org/10.1210/clinem/dgad637

Vancouver

Douglas RS, Couch S, Wester ST, Fowler BT, Liu CY, Subramanian PS, et al. Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity. The Journal of Clinical Endocrinology & Metabolism. 2023;109(1):25-35. doi:10.1210/clinem/dgad637

BibTeX
@article{Douglas2023,
  author = {Douglas, Raymond S and Couch, Steven and Wester, Sara T and Fowler, Brian T and Liu, Catherine Y and Subramanian, Prem S and Tang, Rosa and Nguyen, Quang T and Maamari, Robi N and Ugradar, Shoaib and Hsu, Kate and Karon, Michael and Stan, Marius N},
  title = {Efficacy and Safety of Teprotumumab in Patients With Thyroid Eye Disease of Long Duration and Low Disease Activity},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2023},
  volume = {109},
  number = {1},
  pages = {25--35},
  doi = {10.1210/clinem/dgad637}
}
Kostenlos starten →